| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
William Pridgen last filed a Form 4 in February 2024, as Director at DWTX. From December 2020 to August 2023, the filings on record show 11 open-market purchases and 0 sales. William Pridgen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, William Pridgen's trades have earned a below-average insider score of 28/100 across 9 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -82.3%.
At the last filing, the largest reported position was 52,045 shares of DWTX. Net of sales, the DWTX filings show accumulation of 52,987 shares.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2020 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 1,500 | $11.98 | $17,970.00 | +0.2% |